6 results about "Ethanol Injection" patented technology

The invention provides a lipidosome STING agonist delivery system based on a PD-L1 antibody as well as a preparation method and application of the lipidosome STING agonist delivery system, and belongs to the technical field of medical biology. Preparing lipidosome by adopting an ethanol injection method and an ammonium sulfate gradient technology; the PD-L1 antibody and the STING agonist can be loaded at the same time; the liposome is prepared by adopting an ethanol injection method and an ammonium sulfate gradient technology, and the STING agonist can be wrapped in the liposome in an active drug loading manner; dSPE-PEG2000-NHS and a PD-L1 antibody are mixed and incubated according to a specific proportion by utilizing a post-insertion method to form an antibody conjugated micelle, and the antibody conjugated micelle is fused with a blank liposome to realize antibody modification; secondly, the nano-liposome has good drug carrier characteristics and can effectively protect the loaded drug, reduce the risk of enzymolysis of the drug and improve the stability of the drug in vivo, so that the liposome drug delivery system simultaneously loading the nano-liposome and the nano-liposome is successfully prepared.

The invention discloses a lipid nanoparticle-platelet conjugate as well as a preparation method and application thereof. The conjugate is formed by coupling lipid nanoparticles and platelets through a covalent modification method, a non-covalent modification method or a genetic engineering method, and the lipid nanoparticles can be loaded with nucleic acid, small molecules, protein / polypeptide drugs or CRISPR / Cas system components. The lipid nanoparticles have the drug carrying function of lipid nanoparticles and the natural spleen targeting characteristic of platelets, and the drug uptake rate and delivery efficiency of immune cells can be improved. The preparation method adopts manual mixing, ethanol injection or a microfluidic method, is simple, convenient and efficient, can be completed within several minutes, and does not damage platelets. According to the conjugate, the drug loading type and the coupling mode can be adjusted according to different diseases, the limitation of a single drug carrier is broken through, and the conjugate can adapt to various scenes such as tumor treatment and vaccine delivery and meet the personalized treatment requirement.

This application relates to the fields of chemistry and biomedicine, specifically to a tofenamic acid lipid composition, its preparation method, and its application. A tofenamic acid derivative is obtained by reacting a morpholine solution with tofenamic acid, ethyldimethylaminopropylcarbodiimide, and 4-dimethylaminopyridine, followed by purification. The morpholine in the morpholine solution is an N-alkylmorpholine compound. The tofenamic acid derivative is used to prepare tofenamic acid prodrug liposomes via ethanol injection, which are then used in combination with a STING agonist. The synergistic effect of the combined treatment stems from the dual regulation of the tumor immune microenvironment (TME), overcoming the immune escape induced by STING monotherapy. After STING agonist treatment, the intratumoral COX-2 / PGE2 axis is activated, leading to immunosuppression. The combination of tofenamic acid liposomes and a STING agonist inhibits COX-2, thus relieving this negative feedback loop.

This invention discloses a food-grade nanoliposome and its preparation method. Phosphatidylcholine is dissolved in anhydrous ethanol to obtain an organic phase. Ultrapure water or the water-soluble substance 5(6)-carboxyfluorescein is used as the aqueous phase. The organic and aqueous phases are mixed using a microfluidic method or an ethanol injection method to form a uniform lipid film, resulting in nanoliposomes applicable to the food industry. The aqueous phase is encapsulated within the hydrophilic region of the liposome. Since the liposomes prepared by this invention do not contain cholesterol or other substances besides phosphatidylcholine and have a good encapsulation rate, replacing the aqueous phase with nutrients allows for long-term consumption as food without causing excessive cholesterol levels in the human body. Furthermore, the encapsulation of nutrients by liposomes can improve the absorption of nutrients by the human body, demonstrating significant application potential in the food industry.

The application discloses a phospholipid-epicatechin liposome and a preparation method and application thereof, and relates to the field of food preservation technology. The preparation method of the phospholipid-epicatechin liposome comprises the following steps: taking a functional phospholipid fraction as a membrane material, taking epicatechin as an active component, and preparing the phospholipid-epicatechin liposome by an ethanol injection-ultrasonic method; and the functional phospholipid fraction is prepared by taking low-value sturgeon caviar as raw material, extracting by chloroform-methanol and purifying by silica gel column chromatography. The phospholipid-epicatechin liposome provided by the application can be applied to sturgeon caviar preservation, can effectively delay product brightness attenuation, inhibit abnormal accumulation of volatile basic nitrogen and malondialdehyde, retard excessive degradation of protein, and maximally retain key functional fatty acids such as EPA and DHA in the caviar.

The application discloses an OCTN1-mitochondria double-targeting cascade delivery liposome of ergothioneine, a preparation method and application thereof, and belongs to the technical field of functional cosmetics and targeted drug preparations. The application adopts an ethanol injection method combined with a pH gradient active drug loading technology to prepare a core drug loading liposome, and sequentially modifies ceramide 3, an OCTN1 targeting ligand and a mitochondria targeting ligand on the surface, so as to construct a three-step cascade delivery system of efficient transdermal active cell uptake and mitochondria precise enrichment. The prepared liposome has an encapsulation efficiency of no less than 88%, a drug loading amount of no less than 9.8%, a 24h in-vitro transdermal cumulative permeation amount of no less than 15 mu g / cm 2 , an intracellular mitochondria enrichment rate of no less than 65%, and a mitochondria ROS clearance efficiency of no less than 87%, and the antioxidant and anti-photoaging effects of ergothioneine are significantly improved, so that the application can be widely applied to the fields of high-end anti-aging cosmetics, medical repair products and functional skin care products.